Virtual Presentation

Evaluating Long-Term Safety of Aromatase Inhibitors

Source: Management of ER+ Postmenopausal Early Breast Cancer

Evaluating Long-Term Safety of Aromatase Inhibitors


Faculty:

  • Paul E. Goss, MD, PhD, FRCPC, FRCP

CME CREDIT INFORMATION

Release Date: 04/28/08

Expiration Date: 04/27/09


Physicians: maximum of 0.75 AMA PRA Category 1 Credit(s)™

Status: Please log in to view status


Learning Objectives

Upon completion of this activity, participants should be able to:

  • Describe the safety results of clinical trials using tamoxifen and aromatase inhibitors in the treatment of postmenopausal patients with estrogen receptor–positive breast cancer
  • Discuss the role of estrogen in the treatment and prevention of breast cancer
  • Cite the risks and benefits associated with endocrine therapies for breast cancer treatment
  • Recount the effects that aromatase inhibitors have on end organs

CCO Virtual Presentations combine slides with audio commentary by our esteemed faculty. Complete the CME posttest and evaluation after watching the presentation.
Disclaimer: The materials published on the Clinical Care Options Web site reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.

Jointly sponsored by Postgraduate Institute for Medicine and Clinical Care Options, LLC.

Educational grants provided by:

Educational grants support only the CME-certified components of this program.